Etiology and therapeutic management of erythema nodosum during pregnancy: An update

American Journal of Clinical Dermatology

Volumn 14, Issue 3, 2013, Pages 215-222

  Acosta, K Alexandra ^a   Haver, Mary Claire ^a   Kelly, Brent ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLCHICINE; CORTICOSTEROID; DAPSONE; DEFLAZACORT; HYDROXYCHLOROQUINE; ICHTHAMMOL; INDOMETACIN; INFLIXIMAB; NAPROXEN; OXYPHENBUTAZONE; POTASSIUM IODIDE;

ADAPTIVE IMMUNITY; ANALGESIA; B LYMPHOCYTE; BLEEDING; BLOOD CELL COUNT; CELL DIVISION; CELL MATURATION; CHROMOSOME ABERRATION; CLEFT FACE; CLINICAL EVALUATION; CONGENITAL MALFORMATION; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; ENZYME INHIBITION; ERYTHEMA NODOSUM; ERYTHEMA NODOSUM LEPROSUM; FIRST TRIMESTER PREGNANCY; GOITER; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; INCIDENCE; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; INNATE IMMUNITY; IONIZING RADIATION; LYMPHOMA; MEDLINE; NEUTROPHIL CHEMOTAXIS; ORAL CONTRACEPTION; PREGNANCY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SARCOIDOSIS; SKIN BIOPSY; SKIN TUBERCULOSIS; SUPERFICIAL THROMBOPHLEBITIS; THIRD TRIMESTER PREGNANCY; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

DERMATOLOGIC AGENTS; ERYTHEMA NODOSUM; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SKIN;

EID: 84878749391     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0024-x     Document Type: Review

References (69)

1. Mana J, Marcoval J. Erythema nodosum. Clin Dermatol. 2007;25(3):288-94.
2. Brodell RT, Mehrabi D. Underlying causes of erythema nodosum: lesions may provide clue to systemic disease. Postgrad Med. 2000;108(6):147-9.
3. Hannuksela M. Erythema nodosum. Clin Dermatol. 1986;4(4):88-95.
4. Bartelsmeyer JA, Petrie RH. Erythema nodosum, estrogens, and pregnancy. Clin Obstet Gynecol. 1990;33(4):777-81.
5. Fitzpatrick TB, Klaus W. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill Medical; 2008.
6. Requena L, Yus ES. Erythema nodosum. Semin Cutan Med Surg. 2007;26(2):114-25.
7. Psychos DN, Voulgari PV, Skopouli FN, et al. Erythema nodosum: the underlying conditions. Clin Rheumatol. 2000;19(3):212-6.
8. Garcia-Porrua C, Gonzalez-Gay MA, Vazquez-Caruncho M, et al. Erythema nodosum: etiologic and predictive factors in a defined population [Erratum appears in Arthritis Rheum 2000;43(5):1061]. Arthritis Rheum. 2000;43(3):584-92.
9. Cribier B, Caille A, Heid E, et al. Erythema nodosum and associated diseases: a study of 129 cases. Int J Dermatol. 1998;37(9):667-72.
10. Puavilai S, Sakuntabhai A, Sriprachaya-Anunt S, et al. Etiology of erythema nodosum. J Med Assoc Thail. 1995;78(2):72-5.
11. Requena L, Yus ES. Panniculitis: part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001;45(2):163-83 (quiz 84-6).
12. Miescher G. Histologic diagnosis of erythema nodosum. Dermatologica. 1950;101(4-5):255-6.
13. LeBoit PE. From Sweet to Miescher and back again. Am J Dermatopathol. 2006;28(4):381-3.
14. Bombardieri S, Munno OD, Di Punzio C, et al. Erythema nodosum associated with pregnancy and oral contraceptives. BMJ. 1977;1(6075):1509-10.
15. Jelinek JE. Oral contraceptives and the skin. Am Fam Phys. 1971;4(5):68-74.
16. Gelfand M. Oral contraceptives and erythema nodosum: report of a case. Cent Afr J Med. 1982;28(8):199-201.
17. Baker H. Adverse cutaneous reaction to oral contraceptives. Br J Dermatol. 1969;81(12):946-9.
18. Merk H, Ruzicka T. Oral contraceptives as a cause of erythema nodosum. Arch Dermatol. 1981;117(8):454.
19. Baden HP, Holcomb FD. Erythema nodosum from oral contraceptives. Arch Dermatol. 1968;98(6):634-5.
20. Papagrigoraki A, Gisondi P, Rosina P, et al. Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol. 2010;20(6):773-7.
21. Jeon HC, Choi M, Paik SH, et al. A case of assisted reproductive therapy-induced erythema nodosum. Ann Dermatol. 2011;23(3):362-4.
22. Yang SG, Han KH, Cho KH, et al. Development of erythema nodosum in the course of oestrogen replacement therapy. Br J Dermatol. 1997;137(2):319-20.
23. Jhaveri K, Halperin P, Shin SJ, et al. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat. 2007;106(3):315-8.
24. Jones JV, Cumming RH, Asplin CM. Evidence for circulating immune complexes in erythema nodosum and early sarcoidosis. Ann N Y Acad Sci. 1976;278:212-9.
25. Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol. 1996;106(1):127-33.
26. Piccinni MP, Giudizi MG, Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol. 1995;155(1):128-33.
27. Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Investig. 2002;109(12):1625-33.
28. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001;167(4):1886-90.
29. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood. 2000;95(6):2059-67.
30. Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol. 1979;122(5):1978-85.
31. Munroe JS. Progesteroids as immunosuppressive agents. J Reticuloendothel Soc. 1971;9(4):361-75.
32. Mori T, Kobayashi H, Nishimoto H, et al. Inhibitory effect of progesterone and 20 alpha-hydroxypregn-4-en-3-one on the phytohemagglutinin- induced transformation of human lymphocytes. Am J Obstet Gynecol. 1977;127(2):151-7.
33. Akdis AC, Kilicturgay K, Helvaci S, et al. Immunological evaluation of erythema nodosum in tularaemia. Br J Dermatol. 1993;129(3):275-9.
34. Ryan T. Cutaneous vasculitis. In: Champion R, Burton J, Burns D, et al., editors. Textbook of dermatology. Oxford: Blackwell; 1998. p. 2155-225.
35. Wetherill JH. Recurrent erythema nodosum of pregnancy. BMJ. 1971;3(5773):535.
36. Daw E. Recurrent erythema nodosum of pregnancy. BMJ. 1971;2(5752):44.
37. Schulz EJ, Whiting DA. Treatment of erythema nodosum and nodular vasculitis with potassium iodide. Br J Dermatol. 1976;94(1):75-8.
38. Horio T, Imamura S, Danno K, et al. Potassium iodide in the treatment of erythema nodosum and nodular vasculitis. Arch Dermatol. 1981;117(1):29-31.
39. Marshall JK, Irvine EJ. Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide. Can J Gastroenterol. 1997;11(6):501-2.
40. Cohen S, Benacerraf B, McCluskey RT, et al. Effect of anticoagulants on delayed hypersensitivity reactions. J Immunol. 1967;98(2):351-8.
41. Honma K, Saga K, Onodera H, et al. Potassium iodide inhibits neutrophil chemotaxis. Acta Dermato-Venereol. 1990;70(3):247-9.
42. Briggs GGFRK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
43. Katzung BG, Masters SB, Trevor AJ, et al. Basic and clinical pharmacology. New York: McGraw-Hill Medical; 2012.
44. Golding D. Treating erythema nodosum. BMJ. 1969;4(5682):560-1.
45. Ubogy Z, Persellin RH. Suppression of erythema nodosum by indomethacin. Acta Dermato-Venereol. 1982;62(3):265-6.
46. Mert A, Ozaras R, Tabak F, et al. Erythema nodosum: an experience of 10 years. Scand J Infect Dis. 2004;36(6-7):424-7.
47. Marpeau L, Bouillie J, Barrat J, et al. Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn Ther. 1994;9(2):110-5.
48. Rasanen J, Jouppila P. Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am J Obstet Gynecol. 1995;173(1):20-5.
49. Cunningham FG, Williams JW. Williams obstetrics. New York: McGraw-Hill Medical; 2010.
50. Imboden JB, Hellmann DB, Stone J. Current diagnosis and treatment in rheumatology. New York: London: McGraw-Hill Medical, 2006.
51. Buckshee K, Chadha S. Post tonsillitic erythema nodosum in pregnancy. Int J Gynaecol Obstet. 1996;55(3):293-4.
52. Langer R, Bukovsky I, Lipshitz I, et al. Erythema nodosum associated with pregnancy: case reports. Eur J Obstet Gynecol Reprod Biol. 1979;9(6):399-401.
53. Goodman LS, Brunton LL, Chabner B, et al. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill Medical; 2011.
54. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology. 2006;45(3):348-52.
55. Salvatore MA, Lynch PJ. Erythema nodosum, estrogens, and pregnancy. Arch Dermatol. 1980;116(5):557-8.
56. Coaccioli S, Donati L, Di Cato L, et al. Onset of erythema nodosum during pregnancy: a case report. Clin Exp Obstet Gynecol. 1998;25(1-2):40-1.
57. Labunski S, Posern G, Ludwig S, et al. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Dermato-Venereol. 2001;81(1):18-21.
58. Boyd AS. Etanercept treatment of erythema nodosum. Skinmed. 2007;6(4):197-9.
59. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37(2):150-4.
60. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31(6):823-4.
61. Neblett TR, Burnham TK, Kay N. Chloroquine: its mechanism of action upon immune phenomena. Arch Dermatol. 1965;92(6):720-5.
62. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82-91.
63. Alloway JA, Franks LK. Hydroxychloroquine in the treatment of chronic erythema nodosum. Br J Dermatol. 1995;132(4):661-2.
64. McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis. 2001;33(12):2009-16.
65. McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg. 2002;96(2):180-4.
66. Goodman LS, Brunton LL, Chabner B, et al. Goodman and Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill; 2011.
67. Wallace SL. Erythema nodosum treatment with colchicine. JAMA. 1967;202(11):1056.
68. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001;44(11):2686-92.
69. Brownlie A. Ichthyol and its uses in some skin diseases. The Lancet. 1900;156(4030):1491-2.